Skip to content
Search

Latest Stories

Top Stories

Dark magic: Drug companies and the art of deception

Dark magic: Drug companies and the art of deception
Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Magicians know the key to a convincing trick is misdirection.


They instruct you to follow the left hand so that you’ll ignore the right, which is subtly palming a ball or pulling an ace from the sleeve. The art of the illusion hinges on the magician’s ability to divert attention from where the real action is happening. And, therefore, every illusion conceals the truth.

Similarly, the U.S. biopharmaceutical industry has relied on subtle forms of misdirection in response to increased scrutiny from Congress, the Biden administration and health policy experts.

Here are three illusions drug companies have crafted to maintain massive profitability:

Illusion No. 1: A Death-Defying Feat

Drug research and development (R&D) has, for decades, gifted humanity with medical wonders: antibiotics, statins, cancer therapies and HIV/AIDS treatments.

In the 21st century, however, drug innovation has slowed while pharma companies have made exorbitant pricing a key business strategy. Over the past 18 years, biopharma companies have earned an average gross profit margin of 77%. Last year, the five largest pharma firms generated more than $81.9 billion in profits.

To combat runaway drug prices, Congress passed the Inflation Reduction Act last year, allowing the U.S. government to negotiate prices for a limited number of expensive medications starting in 2026.

The pharmaceutical sector immediately filed lawsuits. In public remarks, drug spokespeople have created the illusion that any reduction in drug-industry profits will destroy R&D innovation and harm millions of patients.

The Hidden Truth

Hidden in this illusion are three facts drug companies don’t want Americans to know. Combined, these truths tell a different story about pharmaceutical research and development.

First, an overwhelming percentage of drug prices gets channeled into corporate profits and administrative costs, not R&D. In fact, a report during the height of the pandemic found that 7 in 10 major drug companies spent more on marketing and sales than R&D.

Second, research concludes that price constraints would minimally impact drug discovery. The Congressional Budget Office estimates that reducing the pharmaceutical revenues would result in just one less drug over the next decade and a total of 1% fewer medications over the next 30 years.

The third and most pernicious part of the illusion is getting people to ignore how many Americans are harmed by the unaffordability of life-essential medications. One example is insulin prices, which have tripled over the past decade. As a result, researchers from Yale found 25% of children with type 1 diabetes are given lower doses by their parents than their physicians recommend.

Nearly 1 in 4 Americans on prescription drugs now report difficulty affording their medications. That is the hidden truth. Exorbitant Rx prices hurt and kill far more Americans than the supposed loss of R&D ever would.

Illusion No. 2: The Statue Of Liberty Trick

Once Americans buy into the illusion that exorbitant drug prices are necessary to save lives, pharmaceutical companies move on to the next sleight of hand.

It goes like this: The United States, alone, must shoulder the enormous burden of drug prices.

Right now, Americans pay 2.4 to 3.4 times more for medications than in peer nations.

Much of the disparity in spending dates back to 2003 when Congress passed a law prohibiting the U.S. government from negotiating drug prices. And without any pricing regulations in place, domestic drug companies have pushed the boundaries ever higher. Over the past two years, nearly half of FDA approved medications have debuted above $150,000 with several topping $1 million per patient.

Outside of the United States, excessively high drug prices are a rarity.

Ozempic exemplifies the problem. This diabetes drug helps people lose significant weight while also avoiding heart attacks. A month’s supply of it costs $936 in the United States. In Japan, it sells for $169. It’s just $93 in the UK, $87 in Australia and $83 France.

Each of these countries has instituted drug-pricing controls and caps on drugmaker profits. If our nation adopted the same regulations, we could prescribe Ozempic to every overweight and obese American, and affordably solve the obesity epidemic. But under current retail pricing, doing so would increase drug spending $1.5 trillion per year, raising overall healthcare costs by 25%.

The Hidden Truth

The illusion here is that drug prices in other wealthy nations are non-negotiable.

But of course, that’s not accurate. American drug companies could play hardball with peer countries, refusing to sell their medications unless a more equitable pricing structure can be reached.

But why bother when you can simply stick Americans with the bill?

Illusion No. 3: What’s In Your Pocket?

When it comes to purchasing prescription drugs, there are two prices. There’s the very high retail price drug companies charge and the much-smaller amount insured patients pay when they pick up their medications (the out-of-pocket expense).

Since out-of-pockets are only small fraction of the total drug expense, drug companies would like Americans to concentrate on those dollars. But that requires people to assume the rest of the money—paid by the government or private businesses—is free.

The Hidden Truth

The reality is that workers and taxpayers wind up paying the price for expensive medications in two ways:

1. Workers earn less pay as benefit costs increase. That’s because employers treat wages and healthcare benefits as a single expense. As medical costs soar, raises disappear and salaries stagnate.

2. Taxpayers either pay more or get less. When medical costs rise, the government must either raise taxes or cut programs, including school funding and public safety.

Deception and misdirection can be sources of wonder at magic shows. But illusions in healthcare prove to be disturbing, dangerous and deadly.

Read More

We Are Not Going Back to the Sidelines!

Participants of the seventh LGBTIQ+ Political Leaders Conference of the Americas and the Caribbean.

Photograph courtesy of Siara Horna. © liderazgoslgbt.com/Siara

We Are Not Going Back to the Sidelines!

"A Peruvian, a Spaniard, a Mexican, a Colombian, and a Brazilian meet in Lima." This is not a cliché nor the beginning of a joke, but rather the powerful image of four congresswomen and a councilwoman who openly, militantly, and courageously embrace their diversity. At the National Congress building in Peru, the officeholders mentioned above—Susel Paredes, Carla Antonelli, Celeste Ascencio, Carolina Giraldo, and Juhlia Santos—presided over the closing session of the seventh LGBTIQ+ Political Leaders Conference of the Americas and the Caribbean.

The September 2025 event was convened by a coalition of six organizations defending the rights of LGBTQ+ people in the region and brought together almost 200 delegates from 18 countries—mostly political party leaders, as well as NGO and elected officials. Ten years after its first gathering, the conference returned to the Peruvian capital to produce the "Lima Agenda," a 10-year roadmap with actions in six areas to advance toward full inclusion in political participation, guaranteeing the right of LGBTQ+ people to be candidates—elected, visible, and protected in the public sphere, with dignity and without discrimination. The agenda's focus areas include: constitutional protections, full and diverse citizenship, egalitarian democracy, politics without hate, education and collective memory, and comprehensive justice and reparation.

Keep ReadingShow less
ICE’s Growth Is Not Just an Immigration Issue — It’s a Threat to Democracy and Electoral Integrity

ICE’s Growth Is Not Just an Immigration Issue — It’s a Threat to Democracy and Electoral Integrity

Getty Images

ICE’s Growth Is Not Just an Immigration Issue — It’s a Threat to Democracy and Electoral Integrity

Tomorrow marks the 23rd anniversary of the creation of the U.S. Immigration and Customs Enforcement (ICE). Created in the aftermath of 9/11, successive administrations — Republican and Democrat — have expanded its authority. ICE has become one of the largest and most well-funded federal law enforcement agencies in U.S. history. This is not an institution that “grew out of control;” it was made to use the threat of imprisonment, to police who is allowed to belong. This September, the Supreme Court effectively sanctioned ICE’s racial profiling, ruling that agents can justify stops based on race, speaking Spanish, or occupation.

A healthy democracy requires accountability from those in power and fair treatment for everyone. Democracy also depends on the ability to exist, move, and participate in public life without fear of the state. When I became a U.S. citizen, I felt that freedom for the first time free to live, work, study, vote, and dream. That memory feels fragile now when I see ICE officers arrest people at court hearings or recall the man shot by ICE agents on his way to work.

Keep ReadingShow less
Meet the Faces of Democracy: Toya Harrell

Toya Harrell.

Issue One.

Meet the Faces of Democracy: Toya Harrell

Editor’s note: More than 10,000 officials across the country run U.S. elections. This interview is part of a series highlighting the election heroes who are the faces of democracy.


Toya Harrell has served as the nonpartisan Village Clerk of Shorewood, Wisconsin, since 2021. Located in Milwaukee County, the most populous county in the state, Shorewood lies just north of the city of Milwaukee and is the most densely populated village in the state with over 13,000 residents, including over 9,000 registered voters.

Keep ReadingShow less